Total Payments
$270,548
2023 Payments
$158,430
Companies
5
Transactions
28
Payment Breakdown by Category
Research$263,212 (97.3%)
Consulting$5,600 (2.1%)
Travel$1,736 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $263,212 | 19 | 97.3% |
| Consulting Fee | $5,600 | 3 | 2.1% |
| Travel and Lodging | $1,736 | 6 | 0.6% |
Payments by Type
Research
$263,212
19 transactions
General
$7,336
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BioFire Diagnostics, LLC | $156,930 | 3 | $0 (2023) |
| bioMerieux Inc | $106,283 | 16 | $0 (2022) |
| Accelerate Diagnostics Inc. | $5,236 | 7 | $0 (2021) |
| Abbott Laboratories | $1,500 | 1 | $0 (2023) |
| Beckman Coulter, Inc. | $600.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $158,430 | 4 | BioFire Diagnostics, LLC ($156,930) |
| 2022 | $106,283 | 16 | bioMerieux Inc ($106,283) |
| 2021 | $5,236 | 7 | Accelerate Diagnostics Inc. ($5,236) |
| 2017 | $600.00 | 1 | Beckman Coulter, Inc. ($600.00) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/02/2023 | BioFire Diagnostics, LLC | FILMARRAY PNEUMONIA PANEL (PNEUMO) (Device) | — | Cash or cash equivalent | $66,804.50 | Research |
| Category: Diagnostics | ||||||
| 10/02/2023 | BioFire Diagnostics, LLC | FILMARRAY PNEUMONIA PANEL (PNEUMO) (Device) | — | Cash or cash equivalent | $49,562.50 | Research |
| Category: Diagnostics | ||||||
| 02/22/2023 | BioFire Diagnostics, LLC | — | — | Cash or cash equivalent | $40,562.50 | Research |
| 01/05/2023 | Abbott Laboratories | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Rapid Diagnostics | ||||||
| 09/08/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $368.00 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 09/07/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $664.00 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 08/08/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $362.53 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 08/08/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $167.63 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 08/08/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $89.74 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 07/20/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $99,125.00 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 06/14/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $1,327.99 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 05/03/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $362.53 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 05/03/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $167.63 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 05/03/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $89.74 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 04/06/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $368.00 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 04/05/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $1,327.99 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 02/09/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $1,217.41 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 01/25/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $388.59 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 01/25/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $162.47 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 01/25/2022 | bioMerieux Inc | — | — | Cash or cash equivalent | $93.41 | Research |
| Study: Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | ||||||
| 11/10/2021 | Accelerate Diagnostics Inc. | ACCELERATE PHENOTEST BC KIT (Device) | Travel and Lodging | In-kind items and services | $355.61 | General |
| 11/10/2021 | Accelerate Diagnostics Inc. | ACCELERATE PHENOTEST BC KIT (Device) | Travel and Lodging | In-kind items and services | $263.50 | General |
| 11/08/2021 | Accelerate Diagnostics Inc. | ACCELERATE PHENOTEST BC KIT (Device) | Travel and Lodging | In-kind items and services | $320.71 | General |
| 11/07/2021 | Accelerate Diagnostics Inc. | ACCELERATE PHENOTEST BC KIT (Device) | Travel and Lodging | In-kind items and services | $253.50 | General |
| 10/07/2021 | Accelerate Diagnostics Inc. | ACCELERATE PHENOTEST BC KIT (Device) | Travel and Lodging | In-kind items and services | $416.80 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Rapid diagnostic supporting Antimicrobial Stewardship in patients with Pneumonia (RASP) | bioMerieux Inc | $106,283 | 16 |
About Dr. Robin Patel, M.D
Dr. Robin Patel, M.D is a Infectious Disease healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871573212.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robin Patel, M.D has received a total of $270,548 in payments from pharmaceutical and medical device companies, with $158,430 received in 2023. These payments were reported across 28 transactions from 5 companies. The most common payment nature is "" ($263,212).
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Clinical Pathology/Laboratory Medicine, Medical Microbiology
- Location Rochester, MN
- Active Since 01/20/2006
- Last Updated 10/06/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1871573212
Products in Payments
- FILMARRAY PNEUMONIA PANEL (PNEUMO) (Device) $116,367
- ACCELERATE PHENOTEST BC KIT (Device) $5,236
- MicroScan WalkAway (Device) $600.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Rochester
Ann Falsey, Md, MD
Infectious Disease — Payments: $191,692
Infectious Disease $191,692
Edward Walsh, Md, MD
Infectious Disease — Payments: $131,419
Infectious Disease $131,419
Emil Lesho, D.o, D.O
Infectious Disease — Payments: $65,937
Infectious Disease $65,937
Zelalem Temesgen, M.d, M.D
Infectious Disease — Payments: $56,223
Infectious Disease $56,223
Dr. Angela Branche, Md, MD
Infectious Disease — Payments: $50,957
Infectious Disease $50,957
William Valenti, Md, MD
Infectious Disease — Payments: $38,806
Infectious Disease $38,806